Northwestern Medicine
EXPERTS AT THE 2024 American Society of Hematology (ASH) Annual Meeting and Exposition
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition will take place in San Diego, California, and online, starting December 7 through 10, 2024. Featuring multiple opportunities to interact with leaders in the healthcare industry, the ASH annual meeting is the world’s largest and most comprehensive hematology event of the year.
Several physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine Oncology will be among the many speakers and presenters, sharing research, new findings and the latest advances. See the Northwestern Medicine physicians presenting at ASH 2024 below.
Several physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine Oncology will be among the many speakers and presenters, sharing research, new findings and the latest advances. See the Northwestern Medicine physicians presenting at ASH 2024 below.
NORTHWESTERN MEDICINE PRESENTATION HIGHLIGHTS
|
Presenter
|
Date & Time
|
Track & Session
|
|
Lucy A. Godley, MD, Jeffrey and Marianne Silver Family Professor of Oncology, Professor, Medicine (Hematology and Oncology)
|
Friday, December 6, 2024
4:56 - 5:00 pm |
|
|
Friday, December 6, 2024
11:00 am - 2:00 pm |
Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials: Medical Crossfire: Bridging Evidence to Practice in AML
|
|
Peng Ji, MD, Vice Chair for Research, Department of Pathology, Professor, Pathology (Experimental Pathology), Pathology (Hematopathology)
|
Saturday, December 7, 2024
9:30 - 10:45 am |
Scientific Program, Hematology Disease Topics & Pathways: Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology
|
|
Saturday, December 7, 2024
10:30 am |
Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities: Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)
|
|
Saturday, December 7, 2024
5:30 - 7:30 pm |
Hodgkin Lymphomas: Clinical and Epidemiological: Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
|
|
|
Sunday, December 8, 2024
10:30 am |
Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma: Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
|
|
Brandon Elsworth, MD and
Reem Karmali, MD, MS, Associate Professor, Medicine (Hematology and Oncology) |
Sunday, December 8, 2024
1:15 pm |
Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies: Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
|
|
Sunday, December 8, 2024
6:00 - 8:00 pm |
Acute Myeloid Leukemias: Commercially Available Therapies: Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
|
Kehan Ren, PhD, and Peng Ji, MD, Vice Chair for Research, Department of Pathology, Professor, Pathology (Experimental Pathology), Pathology (Hematopathology)
|
Monday, December 9, 2024
3:45 pm |
Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease
Hematology Disease Topics & Pathways: Bone Marrow Microenvironment Dictates the Progression of Clonal Hematopoiesis through Stromal-Macrophage Cell-Cell Interactions |
|
Inci Aydemir, MD, and Peng Ji, MD, Vice Chair for Research, Department of Pathology, Professor, Pathology (Experimental Pathology), Pathology (Hematopathology)
|
Monday, December 9, 2024
6:00 - 8:00 pm |
Bone Marrow Failure and Cancer Predisposition Syndromes: Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids
|
|
Madeline Jenkin, BS, and Jonathan Moreira, MD, Associate Professor, Medicine (Hematology and Oncology)
|
Monday, December 9, 2024
5:00 pm |
T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: Are We Ready to Move the Needle in T Cell Lymphomas? : CTCL Clustering in Iowa, Illinois, and Kentucky and Its Association with Environmental Factors
|
connect with us on social
Use #ASH24 to follow and share insights from the meeting on Twitter, tagging:
- Lurie Cancer Center: @LurieCancer
- Northwestern Medicine: @NorthwesternMed
NORTHWESTERN MEDICINE onCOLOGY
|
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in the treatment of a broad range of cancer types due to its dedication to comprehensive clinical oncology research, world-renowned faculty, physicians and oncologists, and its commitment to making breakthroughs in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 57 comprehensive cancer centers in the nation recognized for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
|